Farzin Haque
Stock Analyst at Jefferies
(3.00)
# 1,279
Out of 5,182 analysts
5
Total ratings
80%
Success rate
63.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Farzin Haque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Initiates: Buy | $50 | $14.12 | +254.11% | 1 | Mar 30, 2026 | |
| RLMD Relmada Therapeutics | Initiates: Buy | $9 | $7.03 | +28.02% | 1 | Dec 22, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $10 | $4.56 | +119.30% | 1 | Sep 30, 2025 | |
| PYXS Pyxis Oncology | Assumes: Buy | $10 | $1.76 | +468.18% | 1 | May 7, 2024 | |
| VERA Vera Therapeutics | Upgrades: Buy | $18 → $26 | $37.28 | -30.26% | 1 | Nov 10, 2023 |
Vor Biopharma
Mar 30, 2026
Initiates: Buy
Price Target: $50
Current: $14.12
Upside: +254.11%
Relmada Therapeutics
Dec 22, 2025
Initiates: Buy
Price Target: $9
Current: $7.03
Upside: +28.02%
Nuvation Bio
Sep 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.56
Upside: +119.30%
Pyxis Oncology
May 7, 2024
Assumes: Buy
Price Target: $10
Current: $1.76
Upside: +468.18%
Vera Therapeutics
Nov 10, 2023
Upgrades: Buy
Price Target: $18 → $26
Current: $37.28
Upside: -30.26%